Loading…

Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors

A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated ag...

Full description

Saved in:
Bibliographic Details
Published in:Archiv der Pharmazie (Weinheim) 2018-04, Vol.351 (3-4), p.e1700311-n/a
Main Authors: Lamie, Phoebe F., Philoppes, John N., Rárová, Lucie
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743
cites cdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743
container_end_page n/a
container_issue 3-4
container_start_page e1700311
container_title Archiv der Pharmazie (Weinheim)
container_volume 351
creator Lamie, Phoebe F.
Philoppes, John N.
Rárová, Lucie
description A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site. A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.
doi_str_mv 10.1002/ardp.201700311
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1994362369</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2020969070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</originalsourceid><addsrcrecordid>eNqFkcFuEzEQhi0EoqFw5YgscSlSknps7258rFKgSJGCEEi9rbzr2dSVY4e1N7A98Qi8C2_Ek-CSUiQuHOyZkb75Nfp_Qp4DmwNj_FT3ZjfnDCrGBMADMoGCw0zCQj4kEybKYlZyIY7IkxivWWYYLx6TI64kYxJgQn6cY7QbP6Vx9Okq93FKtTe0scGFjW21o7jXbtDJBk9DR33Yo6Mw5T-_fTdW96PLjcwvDk1MNg0JTZ4a9DejswY95qk4kRevcrVba_RNVvZIDfZ2n2X3GKmOtB1TSOGrbaneoE_x9xXL9WXe4qer9SW1_so2NoU-PiWPOu0iPrurx-TTm9cflxez1frtu-XZataKSmQTkFUVyEIxBpqjFmVXQbMoFkbqouoaBaoCBFOWDRcFF6Yw-UcjoRXNopLimJwcdHd9-DxgTPXWxhad0x7DEGtQSopsb6ky-vIf9DoMvc_X1ZxxpkrFKpap-YFq-xBjj1296-02e1gDq2_jrG_jrO_jzAsv7mSHZovmHv-TXwbUAfhiHY7_kavPPpy__yv-C_dks5k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2020969070</pqid></control><display><type>article</type><title>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Lamie, Phoebe F. ; Philoppes, John N. ; Rárová, Lucie</creator><creatorcontrib>Lamie, Phoebe F. ; Philoppes, John N. ; Rárová, Lucie</creatorcontrib><description>A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site. A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.</description><identifier>ISSN: 0365-6233</identifier><identifier>EISSN: 1521-4184</identifier><identifier>DOI: 10.1002/ardp.201700311</identifier><identifier>PMID: 29400411</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis ; Anti-Inflammatory Agents, Non-Steroidal - chemistry ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; anti‐inflammatory ; Arachidonate 5-Lipoxygenase - metabolism ; Cell Survival - drug effects ; Cells, Cultured ; Cyclooxygenase 2 - metabolism ; Cyclooxygenase 2 Inhibitors - chemical synthesis ; Cyclooxygenase 2 Inhibitors - chemistry ; Cyclooxygenase 2 Inhibitors - pharmacology ; Cytotoxicity ; diaryl imidazolone derivatives ; Dose-Response Relationship, Drug ; Drug Design ; Humans ; Imidazoles - chemical synthesis ; Imidazoles - chemistry ; Imidazoles - pharmacology ; Lipoxygenase Inhibitors - chemical synthesis ; Lipoxygenase Inhibitors - chemistry ; Lipoxygenase Inhibitors - pharmacology ; Molecular Docking Simulation ; molecular docking study ; Molecular Structure ; Structure-Activity Relationship</subject><ispartof>Archiv der Pharmazie (Weinheim), 2018-04, Vol.351 (3-4), p.e1700311-n/a</ispartof><rights>2018 Deutsche Pharmazeutische Gesellschaft</rights><rights>2018 Deutsche Pharmazeutische Gesellschaft.</rights><rights>2018 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</citedby><cites>FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</cites><orcidid>0000-0003-2477-4900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29400411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamie, Phoebe F.</creatorcontrib><creatorcontrib>Philoppes, John N.</creatorcontrib><creatorcontrib>Rárová, Lucie</creatorcontrib><title>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</title><title>Archiv der Pharmazie (Weinheim)</title><addtitle>Arch Pharm (Weinheim)</addtitle><description>A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site. A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - chemistry</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>anti‐inflammatory</subject><subject>Arachidonate 5-Lipoxygenase - metabolism</subject><subject>Cell Survival - drug effects</subject><subject>Cells, Cultured</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Cyclooxygenase 2 Inhibitors - chemical synthesis</subject><subject>Cyclooxygenase 2 Inhibitors - chemistry</subject><subject>Cyclooxygenase 2 Inhibitors - pharmacology</subject><subject>Cytotoxicity</subject><subject>diaryl imidazolone derivatives</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Imidazoles - chemical synthesis</subject><subject>Imidazoles - chemistry</subject><subject>Imidazoles - pharmacology</subject><subject>Lipoxygenase Inhibitors - chemical synthesis</subject><subject>Lipoxygenase Inhibitors - chemistry</subject><subject>Lipoxygenase Inhibitors - pharmacology</subject><subject>Molecular Docking Simulation</subject><subject>molecular docking study</subject><subject>Molecular Structure</subject><subject>Structure-Activity Relationship</subject><issn>0365-6233</issn><issn>1521-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkcFuEzEQhi0EoqFw5YgscSlSknps7258rFKgSJGCEEi9rbzr2dSVY4e1N7A98Qi8C2_Ek-CSUiQuHOyZkb75Nfp_Qp4DmwNj_FT3ZjfnDCrGBMADMoGCw0zCQj4kEybKYlZyIY7IkxivWWYYLx6TI64kYxJgQn6cY7QbP6Vx9Okq93FKtTe0scGFjW21o7jXbtDJBk9DR33Yo6Mw5T-_fTdW96PLjcwvDk1MNg0JTZ4a9DejswY95qk4kRevcrVba_RNVvZIDfZ2n2X3GKmOtB1TSOGrbaneoE_x9xXL9WXe4qer9SW1_so2NoU-PiWPOu0iPrurx-TTm9cflxez1frtu-XZataKSmQTkFUVyEIxBpqjFmVXQbMoFkbqouoaBaoCBFOWDRcFF6Yw-UcjoRXNopLimJwcdHd9-DxgTPXWxhad0x7DEGtQSopsb6ky-vIf9DoMvc_X1ZxxpkrFKpap-YFq-xBjj1296-02e1gDq2_jrG_jrO_jzAsv7mSHZovmHv-TXwbUAfhiHY7_kavPPpy__yv-C_dks5k</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Lamie, Phoebe F.</creator><creator>Philoppes, John N.</creator><creator>Rárová, Lucie</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2477-4900</orcidid></search><sort><creationdate>201804</creationdate><title>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</title><author>Lamie, Phoebe F. ; Philoppes, John N. ; Rárová, Lucie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - chemistry</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>anti‐inflammatory</topic><topic>Arachidonate 5-Lipoxygenase - metabolism</topic><topic>Cell Survival - drug effects</topic><topic>Cells, Cultured</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Cyclooxygenase 2 Inhibitors - chemical synthesis</topic><topic>Cyclooxygenase 2 Inhibitors - chemistry</topic><topic>Cyclooxygenase 2 Inhibitors - pharmacology</topic><topic>Cytotoxicity</topic><topic>diaryl imidazolone derivatives</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Imidazoles - chemical synthesis</topic><topic>Imidazoles - chemistry</topic><topic>Imidazoles - pharmacology</topic><topic>Lipoxygenase Inhibitors - chemical synthesis</topic><topic>Lipoxygenase Inhibitors - chemistry</topic><topic>Lipoxygenase Inhibitors - pharmacology</topic><topic>Molecular Docking Simulation</topic><topic>molecular docking study</topic><topic>Molecular Structure</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamie, Phoebe F.</creatorcontrib><creatorcontrib>Philoppes, John N.</creatorcontrib><creatorcontrib>Rárová, Lucie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Archiv der Pharmazie (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamie, Phoebe F.</au><au>Philoppes, John N.</au><au>Rárová, Lucie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</atitle><jtitle>Archiv der Pharmazie (Weinheim)</jtitle><addtitle>Arch Pharm (Weinheim)</addtitle><date>2018-04</date><risdate>2018</risdate><volume>351</volume><issue>3-4</issue><spage>e1700311</spage><epage>n/a</epage><pages>e1700311-n/a</pages><issn>0365-6233</issn><eissn>1521-4184</eissn><abstract>A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site. A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29400411</pmid><doi>10.1002/ardp.201700311</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2477-4900</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0365-6233
ispartof Archiv der Pharmazie (Weinheim), 2018-04, Vol.351 (3-4), p.e1700311-n/a
issn 0365-6233
1521-4184
language eng
recordid cdi_proquest_miscellaneous_1994362369
source Wiley-Blackwell Read & Publish Collection
subjects Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis
Anti-Inflammatory Agents, Non-Steroidal - chemistry
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
anti‐inflammatory
Arachidonate 5-Lipoxygenase - metabolism
Cell Survival - drug effects
Cells, Cultured
Cyclooxygenase 2 - metabolism
Cyclooxygenase 2 Inhibitors - chemical synthesis
Cyclooxygenase 2 Inhibitors - chemistry
Cyclooxygenase 2 Inhibitors - pharmacology
Cytotoxicity
diaryl imidazolone derivatives
Dose-Response Relationship, Drug
Drug Design
Humans
Imidazoles - chemical synthesis
Imidazoles - chemistry
Imidazoles - pharmacology
Lipoxygenase Inhibitors - chemical synthesis
Lipoxygenase Inhibitors - chemistry
Lipoxygenase Inhibitors - pharmacology
Molecular Docking Simulation
molecular docking study
Molecular Structure
Structure-Activity Relationship
title Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A49%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis,%20and%20biological%20evaluation%20of%20novel%201,2%E2%80%90diaryl%E2%80%904%E2%80%90substituted%E2%80%90benzylidene%E2%80%905(4H)%E2%80%90imidazolone%20derivatives%20as%20cytotoxic%20agents%20and%20COX%E2%80%902/LOX%20inhibitors&rft.jtitle=Archiv%20der%20Pharmazie%20(Weinheim)&rft.au=Lamie,%20Phoebe%20F.&rft.date=2018-04&rft.volume=351&rft.issue=3-4&rft.spage=e1700311&rft.epage=n/a&rft.pages=e1700311-n/a&rft.issn=0365-6233&rft.eissn=1521-4184&rft_id=info:doi/10.1002/ardp.201700311&rft_dat=%3Cproquest_cross%3E2020969070%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2020969070&rft_id=info:pmid/29400411&rfr_iscdi=true